4SC AG in Talks With 3 Potential Partners for Cancer Drug
Published: Sep 13, 2012
4SC AG (VSC) said it’s in talks with at least three potential partners after patients in a mid-stage clinical trial of its liver cancer drug Resminostat combined with Bayer AG (BAYN)’s Nexavar survived for eight months. “Bayer decidedly has an interest in liver cancer,” 4SC Chief Executive Officer Ulrich Dauer said in a telephone interview today. “It would be negligent not to talk to them,” Dauer said, without confirming 4SC is in negotiations with Bayer. Dauer did not name any other potential partners.